Skip to main content

Editas Medicine

Editas Medicine Inc is an American clinical-stage biopharmaceutical enterprise headquartered in Cambridge, Massachusetts. The company specializes in the research, development, and commercialization of precision genomic medicines utilizing proprietary CRISPR gene editing technologies to treat severe genetic diseases, blood disorders, and inherited conditions. Principal revenue is currently earned through strategic pharmaceutical research collaborations, milestone payments, and capital financing arrangements. Editas Medicine Inc is publicly listed on the Nasdaq Stock Market.

2 of the funds FundTelligence covers report a position in Editas Medicine.

Legal name
Editas Medicine Inc
Sector
Health Care
Country
United States
Funds holding it
2
Exposure themes
Gene Editing, Genetic Medicine, Precision Medicine & Genomics

Funds holding Editas Medicine

Loading...